Effects of Insomnia on Simulated Driving (MK-0000-183-00)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a double-blind, parallel design study in elderly primary insomnia patients and demographically matched controls. The objectives if this study are primarily: 1. To determine if functional deficits in simulated driving performance can be demonstrated in primary insomnia patients, and detected in healthy volunteers, impaired by alcohol; and secondarily: 2. To compare simulated driving performance deficits in elderly primary insomnia patients to those in healthy elderly volunteers impaired by alcohol, for at least one of the following driving endpoints: standard deviation of lane position (SDLP), standard deviation of speed (speed deviation), lane excursions, and a driving composite score.
| Condition | Intervention | Phase |
|---|---|---|
|
Insomnia |
Other: Placebo/ethanol (blinded) |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Parallel Assignment Masking: Double-Blind |
| Official Title: | A Randomized Clinical Trial to Study the Effects of Simulated Driving on Primary Insomniacs |
- Simulated driving variables [ Time Frame: Evaluated on, up to, 3 different days, with 2 driving sessions of ~65 minutes each day. ] [ Designated as safety issue: No ]Simulated driving variables which may include (standard deviation of lane position (SDLP), speed deviation, lane excursions, or a composite score of several driving variables).
| Enrollment: | 76 |
| Study Start Date: | October 2010 |
| Study Completion Date: | September 2011 |
| Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Primary insomnia patients and healthy subjects
Elderly participants, including primary insomnia patients and healthy subjects
|
Other: Placebo/ethanol (blinded)
Elderly participants, including primary insomnia patients and healthy subjects will be administered i.v. ethanol or placebo in a blinded manner
Other Name: Placebo or ethanol (blinded)
|
Eligibility| Ages Eligible for Study: | 65 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria A patient or subject may participate in the study if, at least, the ALL of the criteria below are met.
The participant:
- Is a male or female of non-childbearing potential and 65 years of age or older at prestudy (screening);
- Has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months prior to screening;
- Has a current valid driver's license;
- Their regular bedtime is between 9 pm (21:00) and 12 am (00:00);
- During the study, are willing to refrain from napping;
Additionally, a primary insomnia patient must meet the following inclusion criteria:
- Has a diagnosis of Primary Insomnia;
- Reports total sleep time of < 6 hours on at least 3 out of 7 nights each week during the 4 weeks prior to screening;
- Reports spending 6 to 9 hours nightly in bed on at least 3 out of 7 nights each week during the 4 weeks prior to screening.
Exclusion Criteria :
A patient may not participate in the study if ANY of the criteria below (among others determined by the study staff) apply.
The participant:
- Has visual or auditory impairment;
- Has a history of clinically significant endocrine (including diabetes), gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases;
- Has a history of neoplastic disease ;
- Is taking, or plans to take, one or more of the following medications (non-inclusive), within the 2 weeks prior to screening and throughout the course of the study: Centrally acting anticholinergics or antihistamines; Melatonin; Anticonvulsants; Antipsychotics; Anxiolytics; Benzodiazepines; Hypnotics; Any CNS depressants; Over-the-counter medications that could affect sleep; Stimulants; Diet pills; Anti-depressants; Disulfiram;
- Has a positive screening urine drug test (e.g., positive for benzodiazepines, cannabinoids, cocaine, etc.);
- Has a lifetime history of bipolar disorder, a psychotic disorder, or posttraumatic stress disorder or a psychiatric condition requiring treatment with a prohibited medication; or other current psychiatric condition that, in the investigator's opinion, would interfere with the subject/patient's ability to participate in the study ;
- Has evidence of suicidality;
- Has a history of transmeridian travel (across > 3 time zones or > 3 hour time difference) within two weeks prior to screening or anticipates transmeridian travel during the study;
- Has a history of shift work (defined as permanent night shift or rotating day/night shift work) within the past two weeks prior to screening or anticipates need to perform shift work during the study;
- Has a history or diagnosis of any of following conditions, in the opinion of the investigator: Narcolepsy; Cataplexy (familial or idiopathic); Circadian Rhythm Sleep Disorder; Parasomnia including nightmare disorder, sleep terror disorder, sleepwalking disorder, and REM behavior disorder; Sleep-related Breathing Disorder (obstructive or central sleep apnea syndrome, central alveolar hypoventilation syndrome); Periodic Limb Movement Disorder; Restless Legs Syndrome; Primary Hypersomia; Excessive Daytime Sleepiness (EDS), not attributable to Primary Insomnia
- Has a recent and/or active history of a confounding neurological disorder, including but not limited to: seizure disorder, stroke, transient ischemic attack, multiple sclerosis, cognitive impairment, or significant head trauma with sustained loss of consciousness and residual impairment within the last 10 years;
- Has a history of allergy, exceptional sensitivity, or adverse reaction to alcohol;
- Has a significant history of motion sickness or demonstrates significant simulator sickness during practice drives at screening;
- Consumes excessive amounts of alcohol or subject or patient consumes alcohol to promote sleep (i.e., within 3 hours before going to bed);
- Has never consumed alcohol;
- Consumes excessive amounts of coffee, tea, cola, or other caffeinated beverages.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Merck |
| ClinicalTrials.gov Identifier: | NCT01209728 History of Changes |
| Other Study ID Numbers: | MK-0000-183-00 |
| Study First Received: | September 24, 2010 |
| Last Updated: | November 6, 2012 |
| Health Authority: | United States: Schulman IRB |
Keywords provided by Merck:
|
insomnia insomniacs simulated driving alcohol ethanol |
Additional relevant MeSH terms:
|
Sleep Initiation and Maintenance Disorders Sleep Disorders, Intrinsic Dyssomnias Sleep Disorders Nervous System Diseases Mental Disorders Ethanol |
Anti-Infective Agents, Local Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Central Nervous System Depressants Physiological Effects of Drugs Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 16, 2013